June 7, 2021 05:02 PM EDTUpdated June 8, 07:40 AM
Bioregnum

Just how sad­ly mis­guid­ed is the FDA on ad­u­canum­ab?

I doubt very much that Bio­gen paid any­one at the FDA to get an ap­proval on ad­u­canum­ab with this gen­er­ous (?) la­bel. But if they …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times